- Home
- ACB vs CCCC Comparison
ACB vs CCCC Comparison
Compare ACB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- CCCC
- Stock Information
- Founded
- ACB 2013
- CCCC 2015
- Country
- ACB Canada
- CCCC United States
- Employees
- ACB N/A
- CCCC N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- CCCC Health Care
- Exchange
- ACB Nasdaq
- CCCC Nasdaq
- Market Cap
- ACB 315.4M
- CCCC 405.6M
- IPO Year
- ACB N/A
- CCCC 2020
- Fundamental
- Price
- ACB $5.51
- CCCC $6.25
- Analyst Decision
- ACB Hold
- CCCC Buy
- Analyst Count
- ACB 1
- CCCC 6
- Target Price
- ACB N/A
- CCCC $10.50
- AVG Volume (30 Days)
- ACB 659.5K
- CCCC 731.1K
- Earning Date
- ACB 11-07-2024
- CCCC 10-30-2024
- Dividend Yield
- ACB N/A
- CCCC N/A
- EPS Growth
- ACB N/A
- CCCC N/A
- EPS
- ACB N/A
- CCCC N/A
- Revenue
- ACB $203,838,819.00
- CCCC $29,378,000.00
- Revenue This Year
- ACB $14.04
- CCCC $39.70
- Revenue Next Year
- ACB $8.94
- CCCC N/A
- P/E Ratio
- ACB N/A
- CCCC N/A
- Revenue Growth
- ACB 12.30
- CCCC 83.26
- 52 Week Low
- ACB $2.84
- CCCC $1.06
- 52 Week High
- ACB $9.35
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- ACB 46.80
- CCCC 54.57
- Support Level
- ACB $5.46
- CCCC $6.26
- Resistance Level
- ACB $5.66
- CCCC $7.14
- Average True Range (ATR)
- ACB 0.17
- CCCC 0.37
- MACD
- ACB 0.03
- CCCC 0.12
- Stochastic Oscillator
- ACB 71.15
- CCCC 58.99
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.